The metabolic syndrome is a plethora of related disorders that are frequently associated with morbidity and mortality in addition to economic burden. While various treatment options are available, the need to understand the pathology and find new targets still remains. Recent data have suggested GPR75 as one such exciting target that has shown to a highly druggable potential. In this review, we have discussed the recent findings on GPR75 in terms of its expression and signaling and the way it could be a novel target in diseases associated with metabolic syndrome including obesity, dyslipidemia, diabetes, cardiovascular disease, and cerebrovascular disease. In addition, the opportunities and challenges related with the druggable potential of GPR75 have also been highlighted in this review.
Keywords: 20-HETE; CCL5; GPR75; Metabolic syndrome.
Copyright © 2022 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.